Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: A case-only study

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Montes, Ariana ^a   Perez Pampin, Eva ^a   Navarro Sarabia, Federico ^b   Moreira, Virginia ^b   de la Serna, Arturo Rodríguez ^c   Magallares, Berta ^c   Vasilopoulos, Yiannis ^d   Sarafidou, Theologia ^d   Fernández Nebro, Antonio ^e   Ordóñez, María del Carmen ^e   Narváez, Javier ^f   Cañete, Juan D ^g   Marquez, Ana ^h   Pascual Salcedo, Dora ⁱ   Joven, Beatriz ^j   Carreira, Patricia ^j   Moreno Ramos, Manuel J ^k   Caliz, Rafael ^l   Ferrer, Miguel Angel ^l   Garcia Portales, Rosa ^m   Blanco, Francisco J ^n,o   Magro, Cesar ^p   Raya, Enrique ^p   Valor, Lara ^q   Alegre Sancho, Juan J ^r   Balsa, Alejandro ⁱ   Martin, Javier ^h   Plant, Darren ^s   Isaacs, John ^t,u   Morgan, Ann W ^v,w   Barton, Anne ^s,x   Wilson, Anthony G ^y   Gómez Reino, Juan J ^a,o   Gonzalez, Antonio ^a,z   more..

^a Santiago University Clinical Hospital   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d UNIVERSITY OF THESSALY   (Greece)

^e Institute of Biomedical Research in Malaga and BIONAND Nanomedicine Platform   (Spain)

^f HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^m HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

ⁿ HOSPITAL JUAN CANALEJO   (Spain)

^o UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^p HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^q HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^r HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^s MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^t NEWCASTLE UNIVERSITY   (United Kingdom)

^u NEWCASTLE UNIVERSITY   (United Kingdom)

^v ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^w LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^x UNIVERSITY OF MANCHESTER   (United Kingdom)

^y UNIVERSITY COLLEGE DUBLIN   (Ireland)

^z University Hospital of Santiago de Compostela   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; IMMUNOGLOBULIN G1; INFLIXIMAB; METHOTREXATE; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN ALLOTYPE; IMMUNOGLOBULIN G; TUMOR NECROSIS FACTOR;

ADULT; ALLOTYPE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DAS28; FEMALE; FOLLOW UP; GENOTYPE; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; RHEUMATOID ARTHRITIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; GENETICS; IMMUNOLOGY; MIDDLE AGED; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT OUTCOME;

ADALIMUMAB; ADULT; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BASE SEQUENCE; FEMALE; GENOTYPE; HUMANS; IMMUNOGLOBULIN ALLOTYPES; IMMUNOGLOBULIN G; INFLIXIMAB; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84928528146     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0571-z     Document Type: Article

References (48)

1. Smolen JS, Aletaha D, Bijlsma JW, Breedveld FC, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69:631-7.
2. Finckh A, Liang MH, van Herckenrode CM, de Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis. Arthritis Rheum. 2006;55:864-72.
3. Emery P, Dorner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis. 2011;70:2063-70.
4. Isaacs JD, Ferraccioli G. The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis. 2011;70:4-7.
5. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis. 2011;70:1575-80.
6. Isaacs JD, Cohen SB, Emery P, Tak PP, Wang J, Lei G, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis. 2013;72:329-36.
7. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54:711-5.
8. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. Arthritis Rheum. 2006;54:3782-9.
9. Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis. 2007;66:921-6.
10. Radstake TR, Svenson M, Eijsbouts AM, van den Hoogen FH, Enevold C, van Riel PL, et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1739-45.
11. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460-8.
12. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology. 2011;50:1445-52.
13. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune mediated inflammatory conditions: systematic review and metaanalysis. JAMA Intern Med. 2013;173:1416-28.
14. Krintel SB, Grunert VP, Hetland ML, Johansen JS, Rothfuss M, Palermo G, et al. The frequency of anti-infliximab antibodies in patients with rheumatoid arthritis treated in routine care and the associations with adverse drug reactions and treatment failure. Rheumatology. 2013;52:1245-53.
15. Plasencia C, Pascual-Salcedo D, Nuno L, Bonilla G, Villalba A, Peiteado D, et al. Influence of immunogenicity on the efficacy of long term treatment of spondyloarthritis with infliximab. Ann Rheum Dis. 2012;71:1955-60.
16. Jefferis R, Lefranc MP. Human immunoglobulin allotypes: possible implications for immunogenicity. MAbs. 2009;1:332-8.
17. Magdelaine-Beuzelin C, Vermeire S, Goodall M, Baert F, Noman M, Assche GV, et al. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics. 2009;19:383-7.
18. Stickler MM, Reddy A, Xiong JM, Hinton PR, DuBridge R, Harding FA. The human G1m1 allotype associates with CD4+ T-cell responsiveness to a highly conserved IgG1 constant region peptide and confers an asparaginyl endopeptidase cleavage site. Genes Immun. 2011;12:213-21.
19. Tatarewicz SM, Juan G, Swanson SJ, Moxness MS. Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods. 2012;382:93-100.
20. Bartelds GM, de Groot E, Nurmohamed MT, Hart MH, van Eede PH, Wijbrandts CA, et al. Surprising negative association between IgG1 allotype disparity and anti-adalimumab formation: a cohort study. Arthritis Res Ther. 2010;12:R221.
21. Lefranc MP, Lefranc G. The immunoglobulin facts book. London: Academic; 2001.
22. Isaacs JD, Watts RA, Hazleman BL, Hale G, Keogan MT, Cobbold SP, et al. Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet. 1992;340:748-52.
23. Pandey JP, Li Z. The forgotten tale of immunoglobulin allotypes in cancer risk and treatment. Exp Hematol Oncol. 2013;2:6.
24. Pandey JP. Immunoglobulin GM, and KM allotypes and vaccine immunity. Vaccine. 2000;19:613-7.
25. Pandey JP, Luo Y, Elston RC, Wu Y, Philp FH, Astemborski J, et al. Immunoglobulin allotypes influence IgG antibody responses to hepatitis C virus envelope proteins E1 and E2. Hum Immunol. 2008;69:158-64.
26. Kidd MJ, Chen Z, Wang Y, Jackson KJ, Zhang L, Boyd SD, et al. The inference of phased haplotypes for the immunoglobulin H chain V region gene loci by analysis of VDJ gene rearrangements. J Immunol. 2012;188:1333-40.
27. Watson CT, Steinberg KM, Huddleston J, Warren RL, Malig M, Schein J, et al. Complete haplotype sequence of the human immunoglobulin heavy-chain variable, diversity, and joining genes and characterization of allelic and copy-number variation. Am J Hum Genet. 2013;92:530-46.
28. Pandey JP. Genomewide association studies and assessment of risk of disease. N Engl J Med. 2010;363:2076-7. author reply 2077.
29. Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013;9:e1003394.
30. Liu C, Batliwalla F, Li W, Lee A, Roubenoff R, Beckman E, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. Mol Med. 2008;14:575-81.
31. Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG, et al. Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011;63:645-53.
32. Umicevic Mirkov M, Cui J, Vermeulen SH, Stahl EA, Toonen EJ, Makkinje RR, et al. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis. Ann Rheum Dis. 2013;72:1375-81.
33. van Gestel AM, Haagsma CJ, van Riel PL. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum. 1998;41:1845-50.
34. R: A Language and Environment for Statistical Computing. http://www.R-project.org .
35. Heath D. An introduction to experimental design and statistics for biology. Boca Raton, Florida: CRC Press; 1995.
36. Lander E, Kruglyak L. Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat Genet. 1995;11:241-7.
37. Vieland VJ. The replication requirement. Nat Genet. 2001;29:244-5.
38. Guillemin F. Primer: the fallacy of subgroup analysis. Nat Clin Pract Rheumatol. 2007;3:407-13.
39. Rispens T, de Vrieze H, de Groot E, Wouters D, Stapel S, Wolbink GJ, et al. Antibodies to constant domains of therapeutic monoclonal antibodies: anti-hinge antibodies in immunogenicity testing. J Immunol Methods. 2012;375:93-9.
40. Namboodiri AM, Pandey JP. Differential inhibition of trastuzumab- and cetuximab-induced cytotoxicity of cancer cells by immunoglobulin G1 expressing different GM allotypes. Clin Exp Immunol. 2011;166:361-5.
41. Fransen J, van Riel PL. Outcome measures in inflammatory rheumatic diseases. Arthritis Res Ther. 2009;11:244.
42. American College of Rheumatology Committee to Reevaluate Improvement Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57:193-202.
43. van Schouwenburg PA, Krieckaert CL, Rispens T, Aarden L, Wolbink GJ, Wouters D. Long-term measurement of anti-adalimumab using pH-shift-anti-idiotype antigen binding test shows predictive value and transient antibody formation. Ann Rheum Dis. 2013;72:1680-6.
44. Tracey D, Klareskog L, Sasso EH, Salfeld JG, Tak PP. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Ther. 2008;117:244-79.
45. Drug In Focus. Tocilizumab. http://www.genericsweb.com/index.php?object_id=762 .
46. Suzuki T, Ishii-Watabe A, Tada M, Kobayashi T, Kanayasu-Toyoda T, Kawanishi T, et al. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR. J Immunol. 2010;184:1968-76.
47. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res. 2011;39:D1035-41.
48. Shealy DJ, Cai A, Staquet K, Baker A, Lacy ER, Johns L, et al. Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha. MAbs. 2010;2:428-39.